Clinical and Neurobiological Advances in Schizophrenia: Improving Outcomes
Schizophrenia is a chronic and disabling condition that is characterized by positive, negative, and cognitive symptoms. Atypical antipsychotics have greatly advanced the management of schizophrenia, however, unmet needs still remain for patients experiencing adverse events and patients with suboptimal adherence. Pharmacologic approaches to schizophrenia are rapidly changing, with novel medications recently approved or in advanced development. This grand rounds series will provide an update on emerging therapies, their neurobiological rationale, mechanisms of action, and place in therapy. This timely activity will be both informative and relevant to patient care by providing insight into the most recent progress in the pharmacologic treatment of schizophrenia.
- Summarize patient assessment methods for various symptoms in schizophrenia
- Assess current and emerging treatments for symptoms in schizophrenia, including their mechanisms of action, clinical data, and tailoring treatments
- Describe how to integrate new advances to optimize therapeutic outcomes
Leslie Citrome, MD
Clinical Professor of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York
The activity is jointly provided by the University of Cincinnati, Global Education Group, and CMEology. The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians; Global Education Group is an approved provider for continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
- Assessment and pathophysiology
- Assessment of schizophrenia
- Neuropsychologic performance of patients with schizophrenia
- Mechanism of action of antipsychotics
- Neurochemical findings; dopamine, serotonin, glutamate, NMDA
- Potential adverse events with antipsychotics
- Treatment options in those with prior antipsychotic exposure
- Adherence and long-acting agents
- Overview of new and emerging pharmacologic therapies for schizophrenia
- Number needed to treat
- Maintenance trials
- Weight gain, akathisia, and somnolence
- Aripiprazole lauroxil
- Paliperidone (3-month formulation)
- Tardive dyskinesia treatments
- Deutetrabenazine and valbenazine
Lunch will be provided as part of this event.
1 CME offered for MDs / 1 Contact Hour offered for RNs
There is no cost to attend, but spaces are limited. Please register using the below form.